Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids

Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids

Abstract Acquired or de novo resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) is a major challenge to ovarian cancer treatment. Therefore, strategies to overcome PARPi resistance are critical to improve prognosis. The purpose of this study is to evaluate whether inhibition of ADAM17 sen...

Full description

Saved in:
Bibliographic Details
Main Authors: Christoph Rogmans, Jan Dittrich, Emily Hamm, Jörg Paul Weimer, David Holthaus, Norbert Arnold, Inken Flörkemeier, Nicolai Maass, Peer Jansen, Astrid Dempfle, Dirk O. Bauerschlag, Nina Hedemann
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
Ovarian cancer
PARP-inhibitor
Olaparib
Resistance
ADAM17
3D tumor spheroids
Online Access:https://doi.org/10.1038/s41598-024-78442-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-78442-y

Similar Items